234 related articles for article (PubMed ID: 20307403)
1. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations.
Muchmore DB; Vaughn DE
J Diabetes Sci Technol; 2010 Mar; 4(2):419-28. PubMed ID: 20307403
[TBL] [Abstract][Full Text] [Related]
2. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.
Muchmore DB; Vaughn DE
J Diabetes Sci Technol; 2012 Jul; 6(4):764-72. PubMed ID: 22920800
[TBL] [Abstract][Full Text] [Related]
3. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
[TBL] [Abstract][Full Text] [Related]
4. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Vaughn DE
Diabetes Care; 2011 Mar; 34(3):666-8. PubMed ID: 21273493
[TBL] [Abstract][Full Text] [Related]
5. Biosynthetic Human Insulin and Insulin Analogs.
Rodbard HW; Rodbard D
Am J Ther; 2020; 27(1):e42-e51. PubMed ID: 31876563
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
[TBL] [Abstract][Full Text] [Related]
7. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.
Vaughn DE; Muchmore DB
Endocr Pract; 2011; 17(6):914-21. PubMed ID: 22138081
[TBL] [Abstract][Full Text] [Related]
8. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
Chapman TM; Noble S; Goa KL
Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
[TBL] [Abstract][Full Text] [Related]
9. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.
Plank J; Wutte A; Brunner G; Siebenhofer A; Semlitsch B; Sommer R; Hirschberger S; Pieber TR
Diabetes Care; 2002 Nov; 25(11):2053-7. PubMed ID: 12401756
[TBL] [Abstract][Full Text] [Related]
10. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
Lindholm A; Jacobsen LV
Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
[TBL] [Abstract][Full Text] [Related]
12. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.
Vaughn DE; Yocum RC; Muchmore DB; Sugarman BJ; Vick AM; Bilinsky IP; Frost GI
Diabetes Technol Ther; 2009 Jun; 11(6):345-52. PubMed ID: 19459762
[TBL] [Abstract][Full Text] [Related]
13. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine.
Ulrich H; Snyder B; Garg SK
Vasc Health Risk Manag; 2007; 3(3):245-54. PubMed ID: 17703632
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
Vignati L; Anderson JH; Iversen PW
Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449
[TBL] [Abstract][Full Text] [Related]
16. Insulin lispro: its role in the treatment of diabetes mellitus.
Campbell RK; Campbell LK; White JR
Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
Roach P; Woodworth JR
Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase.
Morrow L; Muchmore DB; Hompesch M; Ludington EA; Vaughn DE
Diabetes Care; 2013 Feb; 36(2):273-5. PubMed ID: 23043164
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous insulin: pharmacokinetic variability and glycemic variability.
Guerci B; Sauvanet JP
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S7-4S24. PubMed ID: 16389894
[TBL] [Abstract][Full Text] [Related]
20. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
Valensi P; Cosson E
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
